Avid Bioservices Inc (CDMO)

[jakedogman1]

AACR 2018

Rachel Geise, Sadna Budhu, Jedd Wolchok, Taha Merghoub
Ludwig MSK 1:00 - 5:00 PM Section 33, poster board 29 Poster Session
PO.IM02.03 - Immune Mechanisms Invoked by Therapies 1
2767 / 29 - Phosphatidylserine targeting and radiation
improves survival in a mouse tumor model resistant to
checkpoint blockade

Ludwig Cancer on Twitter_ _Rachel Giese, Taha Merghoub and Jedd Wolchok of Ludwig MSK with their poster at #AACR18 on combining radiotherapy with an antibody against an immunosuppressive molecule to tackle #melanoma that resists checkpoint blocade

https://twitter.com/i/moments/986605034162049027

Rachel Giese, Taha Merghoub and Jedd Wolchok of Ludwig MSK with their poster at #AACR18 on combining radiotherapy with an antibody against an immunosuppressive molecule to tackle #melanoma that resists checkpoint blockade pic.twitter.com/HR27Luc2ca

— Ludwig Cancer (@Ludwig_Cancer) April 16, 2018

https://www.ludwigcancerresearch.org/sites/default/files/media/news-pdf/Ludwig%20Presence%20at%202018%20AACR%20Annual%20Meeting.pdf

The questions I have is what is the status of the IP development and who is behind Oncologie... They don't have shareholders to answer to and the less folks know what they are doing, the better for them. MSK and Ludwig have their hands on the IP... a pretty big market in improving checkpoint response... So who lurks behind the shadows?

When will CDMO see some value from the IP?